Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes. Empagliflozin is an inhibitor of the sodium glucose cotransporter- 2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. Blocking SGLT-2 causes blood glucose to be eliminated through the urine via the urethra. The Empagliflozin phase III clinical trial program will include about 14,500 patients.

June 21, 2017

prudect name : Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development
for the treatment of type 2 diabetes. Empagliflozin is an inhibitor of the sodium glucose cotransporter-
2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic
components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the
blood. Blocking SGLT-2 causes blood glucose to be eliminated through the urine via the urethra.
The Empagliflozin phase III clinical trial program will include about 14,500 patients.
empagliflozin

Synonyms: CAS NO: 864070-44-0Molecular Formula: C₂₃H₂₇ClO₇Molecular Weight: 450.91Purity: 98% minSolubility: in DMSOStorage: -20oC

EW 7197 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18512545